Health Care & Life Sciences » Biotechnology | Matinas BioPharma Holdings Inc.

Matinas BioPharma Holdings Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
2,690.70
3,327.30
4,261.10
7,461.90
12,546.80
Other Current Assets
114.40
231.80
304.40
502.00
538.60
Total Current Assets
2,805.10
3,559.10
4,565.50
7,964.00
13,085.50
Net Property, Plant & Equipment
340.00
377.70
356.10
1,569.90
2,042.90
Intangible Assets
-
4,353.90
4,353.90
4,353.90
4,353.90
Other Assets
216.30
115.40
540.80
536.00
461
Total Assets
3,361.50
8,406.10
9,816.30
14,423.70
19,943.20
ST Debt & Current Portion LT Debt
-
11.30
128.00
197.20
Accounts Payable
-
-
-
582.90
Other Current Liabilities
1,118.30
1,117.30
1,316.80
1,444.60
Total Current Liabilities
1,118.30
1,128.50
1,444.80
2,224.70
Long-Term Debt
-
-
16.40
67.70
Deferred Taxes
-
1,205.10
1,205.10
848.20
Other Liabilities
15.30
-
-
601.10
Total Liabilities
1,133.60
2,333.70
2,666.40
3,741.70
Common Equity (Total)
2,227.90
6,072.40
1,063.60
4,965.10
Total Shareholders' Equity
2,227.90
6,072.40
7,150.00
10,682.00
Total Equity
2,227.90
6,072.40
7,150.00
10,682.00
Liabilities & Shareholders' Equity
3,361.50
8,406.10
9,816.30
14,423.70
Preferred Stock (Carrying Value)
-
-
6,086.40
5,716.80

About Matinas BioPharma Holdings

View Profile
Address
1545 Route 206 South
Bedminster New Jersey 07921
United States
Employees -
Website http://www.matinasbiopharma.com
Updated 07/08/2019
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its lead anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.